A prospective, multicentre study evaluating safety and efficacy of a fixed dose combination of Remogliflozin etabonate, Vildagliptin, and Metformin in Indian patients with type 2 diabetes mellitus (Triad-RMV)
Prabhat K Agarwal, Divendu Bhushan, Amit Bhate, Sunil Naik, Shailesh Adwani, J S Kushwaha, Sumit Bhushan, Abhishek Mane, Rujuta Gadkari, Sanjay Choudhari, Saiprasad Patil, Hanmant Barkate · 2024
Read A prospective, multicentre study evaluating safety and efficacy of a fixed dose combination of Remogliflozin etabonate, Vildagliptin, and Metformin in Indian patients with type 2 diabetes mellitus (Triad-RMV) by Prabhat K Agarwal, Divendu Bhushan, Amit Bhate, Sunil Naik, Shailesh Adwani, J S Kushwaha, Sumit Bhushan, Abhishek Mane, Rujuta Gadkari, Sanjay Choudhari, Saiprasad Patil, Hanmant Barkate (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11654189.txt.
Description
Prabhat Agarwal and co-authors test a triple drug pill for type 2 diabetes in India. Diabetes affects about eleven percent of adults in India, and many patients stay above sugar targets on two drugs. The study enrolled 215 patients at many centers whose sugar stayed high on a pair of drugs. Each took a fixed pill that joins three drugs in one dose, twice a day.
Blood sugar marks fell a great deal by twelve and twenty-four weeks. At the end, about forty-five percent of patients hit the target level. Kidney measures held steady or improved, and fat levels in blood moved in a good direction. Side effects of note hit under five percent, and none were grave. The authors call the pill safe and effective for this group.
Catalog record
| CREATOR | Prabhat K Agarwal, Divendu Bhushan, Amit Bhate, Sunil Naik, Shailesh Adwani, J S Kushwaha, Sumit Bhushan, Abhishek Mane, Rujuta Gadkari, Sanjay Choudhari, Saiprasad Patil, Hanmant Barkate |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 26 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |